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Alachlor Not Estrogenic
We read with interest the article
"Developmental Effects of Endocrine-
Disrupting Chemicals in Wildlife and
Humans," by Colborn et al. (EHP 101:
378-384). This paper reviews the impor-
tant issue of potential long-term conse-
quences resulting from exposure to
endocrine-disrupting chemicals during
early life. In this article, the authors pri-
marily discuss agents that interfere with the
functioning of endogeneous estrogen. We
would like to bring to your attention an
important factural error in this paper.
Alachlor is listed in Table 1 of that review
as a chemical "reported to have reproduc-
tive and endocrine-disrupting effects."
This assessment is not supported by the
extensive toxicological database on alachlor
and has created the incorrect impression
among some readers that alachlor has
estrogenic activity. Given the importance
ofthis issue in public health, scientific, reg-
ulatory, and legislative arenas, it is neces-
sary to clarify the scientific facts regarding
alachlor and endocrine disruption.
Neither of the references cited by
Colborn et al. (1,2) for alachlor discusses
any data suggesting that it has estrogenic
properties or interferes with reproductive
activity. Both references noted that EPA
concluded that minor kidney changes
observed in some high-dose rats in a repro-
duction study were indicative of a treat-
ment-related effect. This conclusion was
contrary to that of the scientists involved
in the study. Nevertheless, such changes
would not represent reproductive toxicity.
The EPA document (2) mentions the
occurrence ofadrenal tumors in high-dose
female rats, but a more detailed analysis by
the agency subsequently concluded that
these tumors were spontaneous and not
treatment related (3). The only data dis-
cussed in either reference that could be
misinterpreted as a direct effect on any
endocrine system is the occurrence ofthy-
roid neoplasia in rats fed alachlor through-
out their lifetime at a dose that exceeded
the maximum tolerated dose (MTD). It
should be noted that this dose is more than
1 million times higher than EPA's estimate
ofdietary human exposure (4).
The thyroid tumors in rats appear to be
secondary to a hepatic effect rather than a
primary effect of the chemical on the thy-
roid. Results from mechanistic studies have
provided strong evidence indicating that
chronic high-dose alachlor exposure results
in increased thyroid hormone clearance via
induction of hepatic uridine diphosphate
glucuronyl transferase activity, thereby
causing a compensatory increase in circu-
lating thyroid-stimulating hormone levels
followed by hyperplasia and ultimately
neoplasia (5). The vast body of scientific
literature surrounding this general
nongenotoxic mechanism has been evalu-
ated under the auspices of EPA's Risk
Assessment Forum with extensive input
from the scientific and regulatory commu-
nity (6); the process is threshold sensitive
(i.e., there is a dose below which the thy-
roid disturbances and oncogenic response
would not occur).
There are two classes of snythetic
chemicals reported to have estrogenic
activity. The first class, represented by
compounds like op'-DDT, methoxychlor,
and diethylstilbestrol, contain coplanar
rings with chlorine, hydroxy, or methoxy
substituents. The second class contains
multichlorinated caged-ring structures like
chlordecone. Alachlor is not structurally
similar to any ofthese chemicals.
There is another important distinction
between alachlor and several of the estro-
genic compounds (e.g., DDT, PCBs, diox-
ins) discussed by Colborn et al. It was stated
that the latter compounds have a tendency
to persist in human and animal tissues,
appear to sequester in all fatty tissue in the
body, and have been reported in reproduc-
tive tissues. Pharmacokinetic studies in rats,
mice, hamsters, and monkeys (squirrel and
rhesus) have shown that the overall body
clearance ofalachlor is rapid (7-99. A series
of autoradiography studies with alachlor
and its metabolites has been conducted in
rats, mice, hamsters, and monkeys (10,11).
No localization in reproductive or fatty tis-
sue was observed in any of these studies.
This observation has been confirmed by
direct tissue analysis.
A Federal Insectide, Fungicide and
Rodenticide Act-regulated pesticide which
was recently reevaluated and found to have
no toxicology data gaps (12), alachlor has
been extensively investigated in a large
number of studies. These include four rat
and rabbit teratology studies, a three-gen-
eration rat reproduction study including
gross and microscopic analyses of wean-
lings and adults, and several subchronic
and chronic toxicity studies in rats, mice,
and dogs. These studies evaluate a wide
variety of endpoints that detect the effects
of endocrine disruption (e.g., disturbance
of fetal organ differentiation, changes in
vaginal epithelium and prostate, utero-
trophic effects, testicular atrophy/ de-
creased spermatogenesis, altered mating
behavior, decreased fertility/reproductive
success). The results from these numerous
studies have produced no evidence of
estrogenic activity. In addition, alachlor
has been tested for oncogenicity in rats and
mice at dose levels exceeding the MTD
and did not produce tumors in mammary
or other reproductive tissues cited as
potential targets for estrogenic chemicals.
In summary, numerous studies have
been conducted with alachlor at dose levels
exceeding human and wildlife exposure by
many orders of magnitude. These studies
have not revealed any evidence of estro-
genic effects, decreases in fertility/repro-
ductive capacity, or tumors in reproductive
tissues. It is clear that the physical and tox-
icological properties of alachlor are very
different from the endocrine (estrogen)-
disrupting chemicals, and therefore ala-
chlor should not be classified as such.
Wiliam F. Heydens
Thomas W. Fuhremann
Alan G.E. Wilson
TheAgricultural Group
Monsanto Company
St. Louis, Missouri
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Response
Heydens, Fuhremann, and Wilson wrote
their letter under the assumption that in
order to be an endocrine disruptor, a chem-
ical must be estrogenic. We contend that
not all endocrine disrupters are estrogenic.
The term "endocrine disruptor" was select-
ed after many long hours ofdeliberation by
a number of scientists (1). Certainly, any
chemical that increases thyroid hormone
clearance and causes a compensatory
increase in circulating thyroid-stimulating
hormone levels has an "unusual" effect on
the endocrine system.
We tried to make this point in our arti-
cle that differentiation and the life-support
function of the endocrine system are,
indeed, complex processes and continuous-
ly vulnerable to perturbations, either of
endogenous or exogenous source. By limit-
ing the definition of an endocrine disrup-
tor to only estrogenicity, a host of effects
on the developing and functioning
endocrine system would be overlooked.
The purpose ofour article was to bring
to light the complexity of the endocrine
system; the multiple axes of vulnerabiity
during differentiation; the critical nature of
timing of exposure to a chemicals) that
can interfere with the normal synchrony of
physiological systems not only during
embryonic development, but throughout
life; and the fact that vast numbers of
chemicals have become a part of modern
commerce that were never tested for these
effects.
Theo Colborn
World Wildlife Fund
Washington, DC
Fred vom Saal
University ofMissouri
Columbia, Missouri
Ana Soto
Tufts University
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REFERENCES
1. Colborn T, Clement C, eds. Chemically
induced alterations in sexual and functional
development: the wildlife/human connection.
Princeton, NJ:Princeton Scientific Publish-
ing, 1992.
Do The Right TInng...
Get A New Attitude
About Cancer
Ladies 50 or over! Get a new
attitude about life! A new attitude
means taking charge of your
health. Start by getting a
mammogram today. It's the best
way to find breast cancer early.
So please have a mammogram.
Once a year... for a lifetime.
For more information on
mammograms, please call us.
The call is free.
* The 1-0 4 ER
Cancer
Information
Services
THE PUBLIC'S LINK TO CANCER INFORMATION *S tion
Volume 102, Number 3, March 1994 257